Naslov
Low molecular weight heparins (LMWHs) in Croatia: Influence of new clinical guidelines and introduction of oral LMWHs

Autori
Mađarević, Tomislav ; Vitezić, Dinko ; Kučan, Marta ; Gantumur, Monja ; Vitezić, Miomira ; Mršić-Pelčić, Jasenka ; Šestan, Branko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pharmaca 2010 ; 48 (Supp.1): 76-77 / - , 2011

Skup
Second Croatian and First Adriatic Congress on Pharmacoeconomics and Outcomes Research with International Participation

Mjesto i datum
Rovinj, Hrvatska, 06.04.2011. - 09.04.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
low molecular weight heparins; Croatia; clinical guidelines; thromboembolic incidents; medical costs

Sažetak
OBJECTIVE: The aim of this study was to investigate influences of new clinical guidelines for LMWHs therapy and new trends in the usage after introducing oral LMWHs. Oral LMWHs were introduced into the Croatian drug list in 2009. METHODS: The data were obtained from pharmaceutical wholesalers for the ten-year period (2001-2010) (IMS Health database). Financial expenditure data are presented in Croatian Kuna, while drug utilization data are presented in defined daily doses per 1000 inhabitants per day (DDD/1000). We calculated total and hospital consumption of LMWHs and compared shares of oral and subcutaneous LMWHs in hospital and out hospital consumption. RESULTS: In the period 2001-2010 total expenditure increased 3.37 times (11.4 to 38.5 millions) while the related utilization of LMWHs increased 4.66 times (0.42 DDD/1000 to 1.96 DDD/1000). In hospitals 97% of subcutaneous LMWHs were used, while only 46% of oral LMWHs were prescribed in hospitals. A share of oral in total LMWHs usage and expenditure is 1.41%, but increased during one year period for approximately 5 times. CONCLUSION: The usage and financial expenditure of LMWHs in Croatia increased during the investigated period, especially with the introduction of new clinical guidelines for the prevention of thromboembolic incidents. Subcutaneus LMWHs were mostly prescribed in hospitals because its usage required professional application and monitoring. The introduction of oral LMWHs changed that trend and provided self medication at home. That could lead to better patient compliance and decrease of thromboembolic incidents and medical costs in the treatment of medical complications.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA